Phenytoin is regularly employed in the critically ill for prophylaxis against or treatment of seizure disorders. No prior studies have examined current dosing practices in an Australasian intensive care unit (ICU) setting. The aims of this study were to: a) describe the adequacy of contemporary dosing in respect to free and total serum phenytoin concentrations; b) identify factors associated with therapeutic drug concentrations; and c) examine the accuracy of predictive equations that estimate free concentrations in this setting. All patients receiving a loading dose of phenytoin in a tertiary-level ICU were eligible for enrolment; 53 patients were enrolled in the study. Serum samples to determine free and total phenytoin concentrations (measured by high performance liquid chromatography) were then drawn prior to the following dose. Free concentrations below the recommended target (<1 mg/l) were considered as suboptimal. The most common indication for phenytoin loading was traumatic brain injury (49%) and the mean administered dose was 14.5 (3.66) mg/kg. Twenty-six patients (49%) had suboptimal trough free concentrations, although this subgroup was significantly heavier and therefore received a lower per kilogram dose (12.8 [3.1] vs 16.3 [3.4] mg/kg, P=0.001). In multivariate analysis, larger weight adjusted doses (P=0.018), higher albumin concentration (P=0.034) and receiving phenytoin for an indication other than seizure (P=0.035), were associated with a greater likelihood of adequate concentrations. In conclusion, phenytoin dosing remains complex in critically ill patients, although lower per kilogram loading doses are strongly associated with free concentrations below the desired target.
Phenytoin (PTN) has been employed as an effective anticonvulsant agent for more than three decades and is frequently used in the intensive care unit (ICU) for management and prophylaxis of seizures. However, despite significant data on the pharmacokinetics of this drug in various patient groups, difficulties are still experienced in prescribing the correct dose to achieve efficacy without unwanted side-effects (toxicity) in individual patients 1, 2 . This is further complicated by the observation that at therapeutic concentrations, the pharmacokinetics of PTN are non-linear due to capacity-limited hepatic metabolism (Michaelis-Menten kinetics). Consequently, even small increases in PTN doses can lead to disproportionately large and variable increases in serum concentrations 1, 2 .
The complex pharmacokinetics and narrow therapeutic index of PTN requires use of therapeutic drug monitoring when using this agent, with ideal trough total concentrations (PTN total ) between 10 and 20 mg/l using standard assays 3 . Of note, this represents the total measured serum concentration, including both the protein bound and unbound fractions. Under normal conditions PTN is highly protein bound (approximately 90%), predominantly to albumin, leading to free (pharmacologically active) concentrations (PTN free ) of around 1 to 2 mg/l 1, 2 . In this respect, targeting total concentrations in the desired range is only valid if the free fraction remains constant 4 .
PHENYTOIN LOADINg DOSES IN ADULT CRITICAL CARE PATIENTS
Anaesthesia and Intensive Care, Vol. 41, No. 5, September 2013 One factor that causes significant variation in PTN serum protein binding is a low serum albumin concentration (hypoalbuminaemia) leading to an increased PTN free fraction. In this situation the usual PTN total assay, which measures both bound and free portions together, may provide discrepant results relative to the PTN free concentration. In most centres total concentrations only are reported, with adjusted concentrations (for a given albumin value) subsequently calculated using equations such as the Sheiner-Tozer formula 5 . Of note, this equation (similar to many other examples) was developed in a non-critically ill patient population and may not have sufficient accuracy in the ICU.
The large volume of distribution of PTN mandates use of a loading dose to ensure rapid attainment of therapeutic concentrations in blood. However, despite the ubiquity with which this drug is employed and the significant morbidity associated with uncontrolled seizure activity, few studies have investigated the dose-serum concentration relationship under such conditions [6] [7] [8] , particularly in the Australasian context. In this respect, dosing recommendations are largely empirical and poorly validated. Therefore, the objectives of this prospective observational study in critically ill patients were to: a) describe the adequacy of contemporary dosing in respect to free and total serum PTN concentrations; b) identify factors associated with therapeutic drug concentrations; and c) examine the accuracy of predictive equations that estimate free concentrations in this setting.
METHODS
This study was undertaken in an Australian adult tertiary referral, university-affiliated, 30-bed metropolitan ICU over a ten-month period. Patients were included in the study if they were ≥18 years of age, had either central venous or arterial line access as part of routine management (for blood sampling) and were receiving a loading dose of PTN for any reason (e.g. prophylaxis against or treatment of suspected or known seizure activity). Loading doses of PTN used locally are at the clinicians' discretion with no formal guideline in use. As such, this study primarily describes unfiltered PTN prescribing practice in a major Australian institution. Patients were excluded if they were <18 years of age, pregnant, did not provide informed consent, had a dose of PTN prior to admission or received a subsequent dose of PTN prior to completion of sampling. Doses were administered as an intravenous bolus at a rate no greater than 50 mg/minute, consistent with the product information 9 . The Hospital Research and Ethics Committee approved the study and written informed consent was obtained from all patients or a substitute decision maker (Approval No. HREC 2008/134).
Data collection
Admission and demographic data including age, gender, weight, height, body mass index, indication for PTN therapy and Acute Physiology and Chronic Health Evaluation II score 10 were collected on admission. The exact time and dose (in mg) of PTN was recorded prospectively. Three serum PTN concentrations were then obtained prior to the next dose being administered. As this study was entirely observational the time of blood sampling was not precisely specified, with levels being obtained alongside additional laboratory tests. Arterial pH, serum albumin, bilirubin, creatinine and sodium concentrations were measured concurrently.
Assaying free and total phenytoin concentrationsinstrumentation
Chromatography was performed on a 2695 Separations Module with a quaternary solvent manager coupled with a 2996 Photodiode Array Detector (Waters Corporation, Milford, MI, USA). The separation was achieved using an X Bridge C 18 steel cartridge column 2.5 µm, 4.6 × 30 mm, with an inline filter unit (Waters Corporation, Milford, MI, USA). Waters Enterprise Client/Server Empower Chromatography Manager software controlled all system components and acquired and processed the chromatographic data (Waters Corporation, Milford, MI, USA).
Sheiner-Tozer equation
Adjusted PTN (PTN adjust ) concentrations were calculated by applying the Sheiner-Tozer equation to the measured PTN total concentration from the final serum sample. This produces a 'normalised' value on the basis of the measured albumin concentration 5 :
where PTN total is the measured total PTN concentration (in mg/l), α is the normal free fraction, S pat_alb is the patient's measured albumin concentration, and S norm_alb is the normal value for albumin (both measured in g/dl).
Usual values for α (0.10) and S norm_alb (4.4 g/dl) are regularly substituted and the formula then simplified to:
Predicted free phenytoin concentrations (PTN pred_ free ) can then be calculated by multiplying these values by 0.10, as below: Data management Target PTN free concentrations were defined as ≥1 mg/l. Patients were categorised as having either 'adequate' or 'suboptimal' concentrations on this basis, utilising the final measurement (e.g. a serum PTN free concentration ≥1 mg/l in the final sample was considered adequate, whereas <1 mg/l was considered suboptimal). These subgroups were then used in all subsequent univariate comparisons and in multivariate analysis. The additional PTN concentrations were collected to enable population pharmacokinetic analysis, which is still ongoing.
Statistical analysis
Continuous data are expressed as the mean (standard deviation) or median [interquartile range] where non-normally distributed. Categorical data are expressed as counts or percentages. Univariate comparisons employed an independent Student's t-test or Mann-Whitney U test for continuous data, a chi-square or Fisher's exact test for categorical data, where analysis assumptions were met. Correlation between variables used a scatter graph, Pearson correlation coefficient (r) and linear regression.
A multivariate logistic regression model (backward conditional) was constructed to identify factors associated with a greater likelihood of achieving therapeutic PTN free concentrations (≥1 mg/l). Goodness-of-fit was assessed by the Hosmer-Lemeshow statistic and Nagelkerke R 2 value. Precision and bias between PTN free and PTN pred_free concentrations were determined by Bland-Altman analysis. All analyses were performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, USA), and graphPad Prism version 5.0 (graphPad Software, San Diego, CA, USA). A P value <0.05 was considered statistically significant.
RESULTS

Demographic and dosing data
During the study period 1995 patients were admitted to the ICU, of whom 311 had a loading dose of PTN. Fifty-three of these patients were enrolled, with most patients being excluded due to a prior dose being administered outside of the ICU. Demographic, admission, biochemical and dosing data for all patients are presented in Table 1 . The most frequent indication for PTN administration was traumatic brain injury, while the cohort in general was young (mean 48 years), largely male (68%) and overweight (median body mass index 26 kg/m 2 ). Ninety-three percent of patients had a loading dose >10 mg/kg (as recommended by some guidelines 9, 17 ), although they were commonly either 1 g (60%) or 1.5 g (25%) as convenience doses. Trough samples were collected on average 20.4 (4.01) hours post loading dose. The mean measured PTN free was 1.19 (0.64) mg/l and the average unbound drug fraction was approximately 12%. concentrations <10 mg/l, although ~20% (6 of 31) had PTN free concentrations ≥1 mg/l. Only one patient had a PTN total concentration ≥10 mg/l despite a PTN free concentration <1 mg/l. The observed relationship between loading dose (mg/kg) and PTN free and PTN total concentrations is depicted in Figure 1 . A weak, statistically significant correlation between dosing and trough concentrations is demonstrated (PTN total : r=0.398, P=0.007; and PTN free : r=0.433, P=0.003). As presented in Figure 2 , low serum albumin concentrations correlated with an increase in free PTN fraction (r=-0.390, P=0.004), although lower PTN total levels (r=0.318, P=0.020). No significant correlation was observed between pH and free drug fraction.
Concentration data
A backward conditional logistic regression model was constructed to further explore risk factors for suboptimal PTN free concentrations. All the variables listed in Table 2 (other than PTN total concentrations) were entered as categorical or continuous covariates respectively. The results of this analysis are presented in Table 3 . The only statistically significant predictors of an adequate PTN free concentration were a larger per kilogram dose administered (P= 0.018), higher albumin concentrations (P=0.034) and receiving PTN for an indication other than seizure (P=0.035). The Hosmer-Lemeshow test statistic was P=0.340 and R 2 value 0.7, suggesting acceptable goodness-of-fit.
Sheiner-Tozer equation
The Sheiner-Tozer equation was applied to the measured PTN total levels to obtain PTN adjust concentrations using the serum albumin concentration of each patient. PTN pred_free levels were then calculated and compared to the corresponding measured PTN free concentration. As illustrated in Figure 3 , good correlation (r=0.852, P <0.001) was noted across the range of values. The corresponding linear regression equation has a slope of 0.80 (95% confidence interval 0.67 to 0.94), and R 2 value of 0.73. A Bland-Altman plot is presented in Figure 4 . As demonstrated, the bias when using these estimates is relatively low (15.8%), although the equation tends to systematically over-predict the PTN free concentration.
DISCUSSION
In a heterogeneous cohort of critically ill patients receiving clinician-directed loading doses of PTN, this study has demonstrated that in ~50% of cases, PTN free concentrations were suboptimal. This strongly suggests that current PTN dosing practices in a large tertiary-level Australian ICU are poorly suited to rapidly achieving target drug concentrations. Although further data are needed, an appropriate weight-based loading dose was identified in both univariate and multivariate analysis as a key modifiable factor. In this respect, administration of convenience doses of 1 or 1.5 g, which were commonly (n=45) prescribed in this study, represents a grossly simplistic approach that is unlikely to achieve PTN concentrations within the desired range.
Examining previous data concerning the need for appropriate weight-based PTN prescription, Cranford et al 18 reported the adequacy of intravenous loading doses of 12, 15 and 18 mg/kg of PTN in a cohort of patients with either seizures or subarachnoid haemorrhage. They concluded that a dose of 18 mg/kg resulted in therapeutic total concentrations at 24 hours and was safe with respect to cardiovascular stability. Additional work by Wilder et al 19 has also assessed the adequacy of a single loading dose of PTN (mean 13 mg/kg) in 14 patients with seizures. Twelve hours after the infusion the mean concentration of PTN total was 10.21 mg/l, with nine out of the 14 patients having concentrations within the therapeutic range. This decreased to four out of 14 at 24 hours post infusion.
In contrast, Vozeh et al 8 in a study of 49 patients mainly post craniotomy, used Monte Carlo simulations to calculate an optimal dosing scheme for PTN. A total dose of 15 mg/kg, divided into three 5 mg/kg intravenous infusions two hours apart, resulted in 90% of simulated patients having serum concentrations between 10 and 20 mg/l within 6 hours of the first dose being administered. This was then maintained by a 2 mg/kg dose every 12 hours. They concluded that this regimen would avoid the cardiovascular side effects and excessively high serum PTN concentrations seen with total loading doses administered over shorter periods of time 8 .
Blaser et al 6 validated this approach with a study examining the reliability and safety of such a regimen in forty patients receiving PTN for seizure prophylaxis after neurosurgery. Their results demonstrated that 36 out of 40 (90%) patients had serum concentrations within the therapeutic range 12 hours after the completion of the loading dose. In our study however, the focus was on target achievement at 24 hours post first dose and the dosing More recently Martinelli and Muhlebach 7 assessed the adequacy of a 15 mg/kg loading dose of PTN administered over four hours in a cohort of adult hospitalised patients. Their cohort was similar to those included in our study, with the majority suffering traumatic brain injury or seizures. Measured trough total PTN concentrations at 12 hours after the completion of the loading dose (16 hours after the start of therapy) were within the therapeutic range in 77% of cases. They also state that fewer than 10% of patients had a concentration >20 mg/l and that severe hypotension occurred in only two cases during the loading phase 7 .
Our study shows less impressive results, with grossly inadequate free concentrations in those receiving lower mg/kg loading doses. Our work extends these previous data, in that most studies employed PTN total concentrations only and were largely performed in a population of hospitalised patients, rather than the critically ill. As such, ours is one of the few studies to use measured PTN free concentrations, proposing the use of higher mg/kg loading doses to achieve target concentrations of the pharmacologically active fraction of the drug, at 24 hours post loading dose.
Although controversial, a number of pharmacokinetic features of PTN suggest that monitoring of free concentrations is likely to improve efficacy. These include high protein binding, a narrow therapeutic index, a volume of distribution of <2 l/kg, variability in the free fraction depending on albumin concentrations, and free concentrations that reflect the clinical status of the patient equally or better than the total concentration 4, 20, 21 . In addition, others have reported that free concentrations correlate better with toxicity [21] [22] [23] and as such many authors have advocated the need for free PTN monitoring [24] [25] [26] [27] , particularly in patients with hypoalbuminaemia or when co-administering other highly protein bound medications 28 .
The impact of serum albumin concentrations on PTN concentrations is further emphasised by our study findings. As illustrated by the nearly 20% of patients with adequate PTN free levels despite suboptimal total concentrations, changes in drug binding should be more regularly considered in prescribing practice and the interpretation of therapeutic drug monitoring. The correlation between serum albumin concentrations and PTN total concentrations and the greater free drug fraction with hypoalbuminaemia suggests this relationship is complex, mandating further study. The role of bound PTN as a 'drug reservoir', with only free drug available for metabolism and elimination, helps to explain the significance of serum albumin concentrations in the multivariate model.
While hypoalbuminaemia is commonly encountered in the critically ill 29 , the lack of routine 5 . Numerous studies have assessed the accuracy of this approach, with varying results concerning the clinical utility of this equation [30] [31] [32] [33] .
Our results demonstrate a similar bias (15.8%), tending to overestimate free concentrations, although with reasonable correlation. As such, in the absence of an existing free drug assay, Sheiner-Tozer estimates appear to be an acceptable surrogate, although in complex dosing scenarios (such as critical illness) measured free PTN concentrations will remain the gold standard. We would like to acknowledge the following limitations of this study. The study cohort is mixed, with patients receiving PTN for a variety of indications. Although this can be considered a source of confounding, the study was designed to examine the utility of single loading doses in a wide spectrum of critically ill patients, thereby improving its external validity. Despite this, our results primarily reflect PTN dosing at a single institution and therefore may not be reflective of wider practice. The sampling regimen used was also sparse, which limits the data analysis that can be undertaken. However, given the aim of this study was to improve approaches to loading doses of PTN, the methodology was deemed sufficient. Finally, the primary endpoint employed was PTN free concentrations and we have not reported any clinical outcome data. Identifying an attributable effect of inadequate PTN prescription in patients already receiving many drugs with anticonvulsant properties, would require a significantly larger and more costly study. given the established pharmacology of PTN, free drug concentrations were considered as an acceptable surrogate for this analysis.
CONCLUSIONS
This study has shown that currently employed PTN dosing strategies in a large tertiary-level ICU infrequently achieve target-free PTN concentrations. Specifically, higher weight-adjusted doses appear necessary to ensure therapeutic concentrations are achieved in a timely manner. Serum albumin concentrations also appear to significantly impact the probability of achieving adequate PTN concentrations, an area that requires further study. Total PTN concentrations can be adjusted with acceptable confidence using the Sheiner-Tozer equation, allowing greater accuracy in further dose selection. Importantly, the wide inter-patient variability of trough concentrations observed in this study supports the ongoing application of therapeutic drug monitoring to ensure efficacy and limit toxicity of this valuable drug.
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